title: Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients.
abstract: The role of cytogenetic findings in determining the diagnosis, therapy and prognosis of acute myeloid leukaemia (AML) has become more valuable by the day. In this study, the results of conventional and molecular cytogenetic analyses and clinical outcomes of 66 AML patients of different subgroups aged between 16 and 82 were evaluated. Chromosomal abnormalities were detected in 17 (25.7%) patients cytogenetically at the time of diagnosis, whereas molecular cytogenetic abnormalities were detected in 21 (31.8%) patients by fluorescence in situ hybridisation (FISH). Thirty-eight (57.6%) patients had a normal karyotype. In 8 patients, we did not obtain suitable chromosomes for karyotype analysis and in 3 patients conventional cytogenetics were not requested by the physician. During clinical follow-up, 21 patients (31.8%) achieved complete remission (CR), 2 had partial remission (PR) (3.0%) and 4 patients had progressive disease (6.06%). Twenty-eight (42.4%) patients died during treatment and no follow-up data were available in 7 cases. Among patients with chromosome abnormalities detected by either one of the two cytogenetic methods (n=28), 12 had achieved CR, 9 of whom were already categorised in the good prognostic group with t(15;17), inv16 or t(8;21). As for the normal karyotype, each patient displayed a different clinical course, which is probably due to the molecular changes in leukaemia-related genes. Here we report our findings, which correlate with previous reports and conclude that cytogenetics is a crucial marker in leukaemia diagnosis and conventional and molecular cytogenetics should be performed as well as molecular genetic diagnostic methods.
authors.affiliation: Department of Medical Genetics, Faculty of Medicine, Baskent University, Kubilay Sokak No:36 Maltepe, 06570 Ankara, Turkey. feridesahin@hotmail.com
authors.forename: F Iffet
authors.initials: FI
authors.lastname: Sahin
authors.forename: E
authors.initials: E
authors.lastname: Kizilkilic
authors.forename: T
authors.initials: T
authors.lastname: Bulakbasi
authors.forename: Z
authors.initials: Z
authors.lastname: Yilmaz
authors.forename: C
authors.initials: C
authors.lastname: Boga
authors.forename: O
authors.initials: O
authors.lastname: Ozalp
authors.forename: S
authors.initials: S
authors.lastname: Karakus
authors.forename: H
authors.initials: H
authors.lastname: Ozdogu
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003582:Cytogenetics; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D014178:Translocation, Genetic / Q000235:genetics*; D016896:Treatment Outcome